Dr Reddy’s Laboratories, India’s second-largest drugmaker by revenue, reported a 17 per cent drop in its second-quarter profit, pushing its shares down nearly 3 per cent.
The company, whose formulations include drugs for cardiovascular disorders, oncology and pain management, posted a net profit of 5.74 billion rupees ($93.6 million) compared with 6.90 billion rupees a year earlier.
India’s first semiconductor fabrication unit chips in
Q4 Results 2024: Tata Consumer Products, ICICI Prudential Life Insurance, and more to announce earnings today
Tata Consumer Products Q4 Results: Profit down 22.5% at Rs 267.71 crore, revenue up 8.5% on-year
World Earth Day: How ITC’s sustainable packaging solutions are fighting plastic woes
Dr Reddy’s shares were down 2.5 per cent at Rs 3,004 at 0657 GMT in Mumbai, while the broader market was up 0.4 per cent.
